956
Views
14
CrossRef citations to date
0
Altmetric
Report

Elongation of the C-terminal domain of an anti-amyloid β single-chain variable fragment increases its thermodynamic stability and decreases its aggregation tendency

, , , , &
Pages 678-689 | Received 17 Mar 2013, Accepted 12 Jun 2013, Published online: 19 Jun 2013

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (3)

Laia Montoliu-Gaya, Javier Murciano-Calles, Jose C. Martinez & Sandra Villegas. (2017) Towards the improvement in stability of an anti-Aβ single-chain variable fragment, scFv-h3D6, as a way to enhance its therapeutic potential. Amyloid 24:3, pages 167-175.
Read now
Gisela Esquerda-Canals, Joaquim Marti, Geovanny Rivera-Hernández, Lydia Giménez-Llort & Sandra Villegas. (2013) Loss of deep cerebellar nuclei neurons in the 3xTg-AD mice and protection by an anti-amyloid β antibody fragment. mAbs 5:5, pages 660-664.
Read now
Lydia Giménez-Llort, Geovanny Rivera-Hernández, Marta Marín-Argany, José L. Sánchez-Quesada & Sandra Villegas. (2013) Early intervention in the 3xTg-AD mice with an amyloid β-antibody fragment ameliorates first hallmarks of Alzheimer disease. mAbs 5:5, pages 665-864.
Read now

Articles from other publishers (11)

Alejandro R. Roda, Laia Montoliu-Gaya, Gabriel Serra-Mir & Sandra Villegas. (2020) Both Amyloid-β Peptide and Tau Protein Are Affected by an Anti-Amyloid-β Antibody Fragment in Elderly 3xTg-AD Mice. International Journal of Molecular Sciences 21:18, pages 6630.
Crossref
Gisela Esquerda-Canals, Joaquim Martí-Clúa & Sandra Villegas. (2019) Pharmacokinetic parameters and mechanism of action of an efficient anti-Aβ single chain antibody fragment. PLOS ONE 14:5, pages e0217793.
Crossref
Laia Montoliu-Gaya, Sandra D. Mulder, Maaike A.C. Herrebout, Johannes C. Baayen, Sandra Villegas & Robert Veerhuis. (2018) Aβ-oligomer uptake and the resulting inflammatory response in adult human astrocytes are precluded by an anti-Aβ single chain variable fragment in combination with an apoE mimetic peptide. Molecular and Cellular Neuroscience 89, pages 49-59.
Crossref
Laia Montoliu-Gaya & Sandra Villegas. (2018) Immunotherapy for neurodegenerative diseases: the Alzheimer's disease paradigm. Current Opinion in Chemical Engineering 19, pages 59-67.
Crossref
Laia Montoliu-Gaya, Sandra D. Mulder, Robert Veerhuis & Sandra Villegas. (2017) Effects of an Aβ-antibody fragment on Aβ aggregation and astrocytic uptake are modulated by apolipoprotein E and J mimetic peptides. PLOS ONE 12:11, pages e0188191.
Crossref
Adriano Sebollela, Erika N. Cline, Izolda Popova, Kevin Luo, Xiaoxia Sun, Jay Ahn, Milena A. Barcelos, Vanessa N. Bezerra, Natalia M. Lyra e Silva, Jason Patel, Nathalia R. Pinheiro, Lei A. Qin, Josette M. Kamel, Anthea Weng, Nadia DiNunno, Adrian M. Bebenek, Pauline T. Velasco, Kirsten L. Viola, Pascale N. Lacor, Sergio T. Ferreira & William L. Klein. (2017) A human scFv antibody that targets and neutralizes high molecular weight pathogenic amyloid-β oligomers. Journal of Neurochemistry 142:6, pages 934-947.
Crossref
Laia Montoliu-Gaya, Gisela Esquerda-Canals, Silvia Bronsoms & Sandra Villegas. (2017) Production of an anti-Aβ antibody fragment in Pichia pastoris and in vitro and in vivo validation of its therapeutic effect. PLOS ONE 12:8, pages e0181480.
Crossref
Laia Montoliu-Gaya, Jose C. Martínez & Sandra Villegas. (2017) Understanding the contribution of disulfide bridges to the folding and misfolding of an anti-Aβ scFv. Protein Science 26:6, pages 1138-1149.
Crossref
Marta Marin-Argany, Jofre Güell-Bosch, Luis M. Blancas-Mejía, Sandra Villegas & Marina Ramirez-Alvarado. (2015) Mutations can cause light chains to be too stable or too unstable to form amyloid fibrils. Protein Science 24:11, pages 1829-1840.
Crossref
Sandra Villegas. (2015) Enfermedad de Alzheimer: nuevas estrategias terapéuticas. Medicina Clínica 145:2, pages 76-83.
Crossref
Sandra Villegas. (2015) Alzheimer's disease: New therapeutic strategies. Medicina Clínica (English Edition) 145:2, pages 76-83.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.